OWC Pharmaceutical Research Corp (OWCP)

[Kristiansen]

Mr. Mordechai Bignitz said, “Immediately after we announced our cannabinoid-based formulation for our psoriasis treatment, we began receiving requests for the topical psoriasis cream from patients who had been long-time sufferers from the condition. We are very pleased to say that OWC is expecting the topical cream product readiness during 2017 Q2 and, subject to positive completion of our safety IRB approved study and obtaining regulatory approvals from applicable jurisdictions, we should be able to offer our topical cream to those who suffer from psoriasis in the near term.”



That in mind, this catalyst could further push the stock higher. Moreover, if this treatment becomes widely accepted and is approved, the company would be able to significantly grow its revenues and earnings. Consequently, this could translate to an increase in the value of its stock. In addition to this catalyst, some countries have been shifting towards the legalization of cannabis and CBD, which should further propel OWCP higher.